Our study reveals downregulation of ASPP2 can promote the aerobic glycolysis metabolism pathway, increasing HCC proliferation, glycolysis metabolism, stemness and drug resistance. The gene discussed is TP53BP2; the disease is hepatocellular carcinoma.